CAR-T cell therapy Market for Non-Hodgkin Lymphoma is expected to touch USD 2796.2 Million by 2030 – MENAFN.COM

(MENAFN - GetNews) The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) market report provides current treatment practices, emerging therapies, CAR T-Cell Therapy for Non-Hodgkin's lymphoma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Non-Hodgkin's lymphoma market size from 2017 to 2030 segmented by US and EU markets.

DelveInsight's CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Market Insights and Market Forecast-2030 ' report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) and market trends in the 6MM, i.e., the United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).

CAR-T cell therapy market for NHL

The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) market report provides current treatment practices, emerging therapies, CAR T-Cell Therapy for Non-Hodgkin's lymphoma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Non-Hodgkin's lymphoma market size from 2017 to 2030 segmented by US and EU markets. The Report also covers current CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Marketed Therapies in CAR-T cell therapy market for NHL

Chemotherapies, radiation therapies and immunotherapies are either used in combination or alone, depending upon the severity, success rate, age and several other factors. However, CAR-T cell therapy promises one-time treatment and cancer-free life. The available therapeutics treatment options in CAR T-Cell Therapy market for Non-Hodgkin lymphoma aim to kill the leukemia cells in the blood and bone marrow.

The approval of Yescarta was proved to be the light of the day for the group of cancer patients who were left with a few other options, and those with certain types of lymphoma that had not responded to previous treatments.

Emerging Therapies in CAR-T cell therapy market for NHL

This section focusses on the rate of uptake of the potential CAR T-Cell Therapies recently launched in the Non-Hodgkin's lymphoma market or expected to get launched in the market during the study period 20172030. The analysis covers Non-Hodgkin's lymphoma market uptake by CAR T-Cell Therapies; patient uptake by therapies; and sales of each therapy.

The approval of the novel CAR-T cell therapy attracted many pharma investors and pharma companies, highlighting the bright scope of CAR-T cell therapies in oncology.

Several companies, including Celgene , and Gilead , are working to fuel the CAR-T cell therapy market for Non-Hodgkin lymphoma. The expected launch of Lisocabtagene maraleucel (also known as JCAR017) of Celgene 's, (a BMS company) and KTE-X19 by Gilead will significantly drive the NHL market in the near future.

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Non-Hodgkin's lymphoma (NHL) emerging CAR T-Cell Therapies.

Request for Sample Pages

CAR-T cell therapy market for NHL: Forecast

As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030.

Among the EU-5 countries, Germany, Italy and France are observed to be among top holders of the largest CAR T-Cell Therapy market share for Non-Hodgkin lymphoma followed by UK and Spain.

Know more about the scenario of CAR-T Market for NHL

Scope of the Report

Table of Contents

1 Key Insights

2 Executive Summary

3 CAR T-Cell Therapy for NHL Market Overview at a Glance

4 CAR T-Cell Therapy: Background and Overview

5 Treatment Algorithm, Current Treatment, and Medical Practices

6 Unmet Needs

7 Key Endpoints of NHL Treatment

8 Marketed CAR T-Cell Therapies for NHL

8.2 KYMRIAH: NOVARTIS

8.3 YESCARTA: Kite Pharma (Gilead Sciences)

9 Emerging CAR T-Cell Therapies for NHL

9.1.1 KTE-X19: Gilead Sciences

9.1.2 JCAR017: Celgene Corporation (a BMS company)

10 CAR T-Cell Therapy for NHL: Six Major Market Analysis

11 Attribute analysis

12 6MM: Market Outlook

13 CAR T-Cell Therapy for NHL Clinical Trials in 6MM

14 KOL Views CAR T-Cell Therapy for NHL

15 Market Drivers

16 Market Barriers

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Vinita Rakheja Email: Send Email Phone: 9193216187 Address: 304 S. Jones Blvd #2432 Country: United States Website: http://www.delveinsight.com/

MENAFN2204202000703268ID1100068707

See the original post here:
CAR-T cell therapy Market for Non-Hodgkin Lymphoma is expected to touch USD 2796.2 Million by 2030 - MENAFN.COM